Shepparton
Tue, May 19 2026
Preview by Ryan Phelan
10-UNIT GAME PLAN
R3 #3 HITCH TO HIS STAR – 2 units (win)
R4 #8 FENWAY PARK – 2 units (win)
R6 #8 HELLOVATIME – 2 units (win)
R7 #1 SPORTING RAGE – 1 unit (win)
R8 #2 ROCK POSTER – 2 units (win)
R9 #2 HELENSHOPE – 1 unit (win)
EARLY QUADDIE
4,5,6,8,9,10,12/3,6,7,8,11/3,5/1,3,6,8
QUADDIE
1,4,5,6/2,4,6,8/1,2,3,5,8/1,2,8
| R10 10:20pm |
VHRC MAIDEN TROT $6,000 MAIDEN RBD TROTTERS |
1690 Mobile |
| No. | Form | Horse | Trainer | Driver | Class | LPI | Rank | Odds | |
|---|---|---|---|---|---|---|---|---|---|
| 1 | 8540s7 | LOOKAT SPUNKY TROT Dr: Ajay Baker | Sherree Baker | Ajay Baker (C) | 4 | $101 | |||
| 2 | 9s865s | PRINCESS HAZEL Dr: Tony Barresi | Tony Barresi | Tony Barresi | 6 | $71 | |||
| 3 | GALHALLA Dr: John Newberry | John Newberry | John Newberry | 8 | $9.0 | ||||
| 4 | 578689 | ALDEBARAN DENBAY Dr: David Miles | Nick Beale | David Miles | 50% | 4 | $8.5 | ||
| 5 | 557s24 | MI BOW Dr: Ellen Tormey | Ross Graham | Ellen Tormey | 50% | 1 | $3.8 | ||
| 6 | 94s | ISTANBUL Dr: Rebecca Bartley | Rebecca Bartley | Rebecca Bartley | 6 | $1.8 | |||
| 7 | 9s0036 | THE RED AVENGER Dr: Scott Rains | Scott Rains | Scott Rains | 3 | $26 | |||
| ------------------------------ Second Row ------------------------------ | |||||||||
| 8 | 222538 | ALDEBARAN ZANE Dr: Ryan Sanderson | Brooke McPherson | Ryan Sanderson (C) | 2 | $5.0 | |||
SELECTIONS: ISTANBUL (6), ALDEBARAN ZANE (8), MI BOW (5), GALHALLA (3)
OVERVIEW: ISTANBUL (6) is a lightly raced four-year-old with a strong SP profile from his two career starts, despite making mistakes on both occasions. He’s since been spelled and has trialled well in preparation for this. If he brings his manners, he looks the one to beat.
ALDEBARAN ZANE (8) changes stables and has shown this season that a win is not far away. He can trail through softly from the draw and if he begins cleanly will be right in the finish. MI BOW (5) ran second here two starts ago, albeit beaten comfortably, and this isn’t a strong race. GALHALLA (3) has had one inconclusive trial but finds a suitable race to debut, so market support should be monitored.